Abiomed Inc. (NASDAQ:ABMD) – Leerink Swann dropped their FY2017 earnings per share (EPS) estimates for shares of Abiomed in a research report issued to clients and investors on Tuesday. Leerink Swann analyst D. Antalffy now anticipates that the brokerage will post earnings of $1.11 per share for the year, down from their previous forecast of $1.12. Leerink Swann currently has a “Outperform” rating and a $125.00 target price on the stock.
Other analysts also recently issued reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a $125.00 price objective on shares of Abiomed in a report on Friday, June 10th. Zacks Investment Research raised shares of Abiomed from a “hold” rating to a “strong-buy” rating and set a $127.00 price objective for the company in a report on Tuesday, July 5th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $115.59.
Shares of Abiomed (NASDAQ:ABMD) traded up 0.16% during mid-day trading on Friday, reaching $128.62. The company’s stock had a trading volume of 210,426 shares. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 136.83 and a beta of 0.89. Abiomed has a 12 month low of $67.81 and a 12 month high of $131.16. The company’s 50-day moving average is $121.83 and its 200 day moving average is $107.68.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.06. Abiomed had a return on equity of 11.86% and a net margin of 11.75%. The firm earned $103 million during the quarter, compared to the consensus estimate of $97.23 million. During the same period last year, the business posted $0.20 EPS. The business’s revenue was up 40.3% compared to the same quarter last year.
In other Abiomed news, CEO Michael R. Minogue sold 58,710 shares of the business’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $127.00, for a total value of $7,456,170.00. Following the transaction, the chief executive officer now owns 215,782 shares in the company, valued at $27,404,314. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael G. Howley sold 17,853 shares of the business’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $119.20, for a total transaction of $2,128,077.60. Following the completion of the transaction, the vice president now owns 65,558 shares in the company, valued at approximately $7,814,513.60. The disclosure for this sale can be found here. 10.00% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. 1832 Asset Management L.P. purchased a new position in Abiomed during the first quarter worth about $121,655,000. M&T Bank Corp purchased a new position in Abiomed during the first quarter worth about $408,000. Menta Capital LLC boosted its position in Abiomed by 10.0% in the first quarter. Menta Capital LLC now owns 13,223 shares of the company’s stock worth $1,254,000 after buying an additional 1,200 shares during the last quarter. Bessemer Group Inc. boosted its position in Abiomed by 94.3% in the first quarter. Bessemer Group Inc. now owns 1,226 shares of the company’s stock worth $116,000 after buying an additional 595 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Abiomed by 17.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,137,738 shares of the company’s stock worth $107,869,000 after buying an additional 167,040 shares during the last quarter. Hedge funds and other institutional investors own 93.65% of the company’s stock.
Abiomed Company Profile
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.